Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment. In parallel international, multicentre, randomised t...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2003-06, Vol.361 (9375), p.2099-2106 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2106 |
|---|---|
| container_issue | 9375 |
| container_start_page | 2099 |
| container_title | The Lancet (British edition) |
| container_volume | 361 |
| creator | Parmar, M K B Ledermann, J A Colombo, N du Bois, A Delaloye, J-F Kristensen, G B Wheeler, S Swart, A M Qian, W Torri, V Floriani, I Jayson, G Lamont, A Tropé, C |
| description | Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.
In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects.
With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0·82 [95% CI 0·69–0·97], p=0·02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% CI for difference 1–12]), and median survival of 5 months (29 vs 24 months [1–11). 717 patients developed progressive disease or died. The progression-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0·76 [0·66–0·89], p=0·0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4–15]) and in median progression-free survival of 3 months (13 vs 10 months [1–5]).
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy. |
| doi_str_mv | 10.1016/S0140-6736(03)13718-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2069947668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S014067360313718X</els_id><sourcerecordid>2069947668</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-24649ec59f7fed854084d517f6dc13c85d1a916bf71a7544f21b2822ba7547263</originalsourceid><addsrcrecordid>eNqF0c1u1DAQB3ALgehSeASQBRc4uLUdx056QasVlEoVi_jS3izHmWhdJXGwnYU-Da-Kt7uCE3AZy9JvxvL8EXrK6BmjTJ5_okxQIlUhX9LiFSsUq8jmHlowoQQphdrcR4vf5AQ9ivGGUiokLR-iE8YrLkXBFujnB2N7l8wP6PHUzzEXk9w4D6QxEVpstzD4tIVgplu8gxAzsX7cwZicH03_T-9G_N0PkKtLWxygN9Pe-J0JzozYmtFCuMCZ46vV-r04X16uyfrr8iPhZxynjPrH6EFn-ghPjucp-vL2zefVO3K9vrxaLa-JFbJKhAsparBl3akO2qoUtBJtyVQnW8sKW5UtMzWTTaeYUaUQHWdN3gFv9jfFZXGKXhzmTsF_myEmfePnkD8YNaeyroWSssrq-d8Uq2uqFKUso_KAbPAxBuj0FNxgwq1mVO-z03fZ6X0wmhb6Lju9yX3PjsPnZoD2T9cxrAxeHwDkRewcBB2tg7zD1gWwSbfe_eeJX508qag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199077001</pqid></control><display><type>article</type><title>Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial</title><source>MEDLINE</source><source>Business Source Complete</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Parmar, M K B ; Ledermann, J A ; Colombo, N ; du Bois, A ; Delaloye, J-F ; Kristensen, G B ; Wheeler, S ; Swart, A M ; Qian, W ; Torri, V ; Floriani, I ; Jayson, G ; Lamont, A ; Tropé, C</creator><creatorcontrib>Parmar, M K B ; Ledermann, J A ; Colombo, N ; du Bois, A ; Delaloye, J-F ; Kristensen, G B ; Wheeler, S ; Swart, A M ; Qian, W ; Torri, V ; Floriani, I ; Jayson, G ; Lamont, A ; Tropé, C ; The ICON and AGO Collaborators ; ICON and AGO Collaborators</creatorcontrib><description>Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.
In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects.
With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0·82 [95% CI 0·69–0·97], p=0·02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% CI for difference 1–12]), and median survival of 5 months (29 vs 24 months [1–11). 717 patients developed progressive disease or died. The progression-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0·76 [0·66–0·89], p=0·0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4–15]) and in median progression-free survival of 3 months (13 vs 10 months [1–5]).
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(03)13718-X</identifier><identifier>PMID: 12826431</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Baldness ; Cancer ; Cancer therapies ; Carboplatin - administration & dosage ; Chemotherapy ; Cisplatin - administration & dosage ; Clinical trials ; Disease-Free Survival ; Drug Administration Schedule ; Drug dosages ; Fatalities ; Female ; Humans ; Medical treatment ; Middle Aged ; Motivation ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; Paclitaxel ; Paclitaxel - administration & dosage ; Patients ; Platinum ; Quality of Life ; Survival ; Toxicity ; Womens health</subject><ispartof>The Lancet (British edition), 2003-06, Vol.361 (9375), p.2099-2106</ispartof><rights>2003 Elsevier Ltd</rights><rights>Copyright Lancet Ltd. Jun 21, 2003</rights><rights>Copyright Elsevier Limited Jun 21, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-24649ec59f7fed854084d517f6dc13c85d1a916bf71a7544f21b2822ba7547263</citedby><cites>FETCH-LOGICAL-c468t-24649ec59f7fed854084d517f6dc13c85d1a916bf71a7544f21b2822ba7547263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/199077001?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002,64392,64396,72476</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12826431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parmar, M K B</creatorcontrib><creatorcontrib>Ledermann, J A</creatorcontrib><creatorcontrib>Colombo, N</creatorcontrib><creatorcontrib>du Bois, A</creatorcontrib><creatorcontrib>Delaloye, J-F</creatorcontrib><creatorcontrib>Kristensen, G B</creatorcontrib><creatorcontrib>Wheeler, S</creatorcontrib><creatorcontrib>Swart, A M</creatorcontrib><creatorcontrib>Qian, W</creatorcontrib><creatorcontrib>Torri, V</creatorcontrib><creatorcontrib>Floriani, I</creatorcontrib><creatorcontrib>Jayson, G</creatorcontrib><creatorcontrib>Lamont, A</creatorcontrib><creatorcontrib>Tropé, C</creatorcontrib><creatorcontrib>The ICON and AGO Collaborators</creatorcontrib><creatorcontrib>ICON and AGO Collaborators</creatorcontrib><title>Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.
In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects.
With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0·82 [95% CI 0·69–0·97], p=0·02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% CI for difference 1–12]), and median survival of 5 months (29 vs 24 months [1–11). 717 patients developed progressive disease or died. The progression-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0·76 [0·66–0·89], p=0·0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4–15]) and in median progression-free survival of 3 months (13 vs 10 months [1–5]).
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.</description><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Baldness</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carboplatin - administration & dosage</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>Drug Administration Schedule</subject><subject>Drug dosages</subject><subject>Fatalities</subject><subject>Female</subject><subject>Humans</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Motivation</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Patients</subject><subject>Platinum</subject><subject>Quality of Life</subject><subject>Survival</subject><subject>Toxicity</subject><subject>Womens health</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0c1u1DAQB3ALgehSeASQBRc4uLUdx056QasVlEoVi_jS3izHmWhdJXGwnYU-Da-Kt7uCE3AZy9JvxvL8EXrK6BmjTJ5_okxQIlUhX9LiFSsUq8jmHlowoQQphdrcR4vf5AQ9ivGGUiokLR-iE8YrLkXBFujnB2N7l8wP6PHUzzEXk9w4D6QxEVpstzD4tIVgplu8gxAzsX7cwZicH03_T-9G_N0PkKtLWxygN9Pe-J0JzozYmtFCuMCZ46vV-r04X16uyfrr8iPhZxynjPrH6EFn-ghPjucp-vL2zefVO3K9vrxaLa-JFbJKhAsparBl3akO2qoUtBJtyVQnW8sKW5UtMzWTTaeYUaUQHWdN3gFv9jfFZXGKXhzmTsF_myEmfePnkD8YNaeyroWSssrq-d8Uq2uqFKUso_KAbPAxBuj0FNxgwq1mVO-z03fZ6X0wmhb6Lju9yX3PjsPnZoD2T9cxrAxeHwDkRewcBB2tg7zD1gWwSbfe_eeJX508qag</recordid><startdate>20030621</startdate><enddate>20030621</enddate><creator>Parmar, M K B</creator><creator>Ledermann, J A</creator><creator>Colombo, N</creator><creator>du Bois, A</creator><creator>Delaloye, J-F</creator><creator>Kristensen, G B</creator><creator>Wheeler, S</creator><creator>Swart, A M</creator><creator>Qian, W</creator><creator>Torri, V</creator><creator>Floriani, I</creator><creator>Jayson, G</creator><creator>Lamont, A</creator><creator>Tropé, C</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20030621</creationdate><title>Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial</title><author>Parmar, M K B ; Ledermann, J A ; Colombo, N ; du Bois, A ; Delaloye, J-F ; Kristensen, G B ; Wheeler, S ; Swart, A M ; Qian, W ; Torri, V ; Floriani, I ; Jayson, G ; Lamont, A ; Tropé, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-24649ec59f7fed854084d517f6dc13c85d1a916bf71a7544f21b2822ba7547263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Baldness</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carboplatin - administration & dosage</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>Drug Administration Schedule</topic><topic>Drug dosages</topic><topic>Fatalities</topic><topic>Female</topic><topic>Humans</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Motivation</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Patients</topic><topic>Platinum</topic><topic>Quality of Life</topic><topic>Survival</topic><topic>Toxicity</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parmar, M K B</creatorcontrib><creatorcontrib>Ledermann, J A</creatorcontrib><creatorcontrib>Colombo, N</creatorcontrib><creatorcontrib>du Bois, A</creatorcontrib><creatorcontrib>Delaloye, J-F</creatorcontrib><creatorcontrib>Kristensen, G B</creatorcontrib><creatorcontrib>Wheeler, S</creatorcontrib><creatorcontrib>Swart, A M</creatorcontrib><creatorcontrib>Qian, W</creatorcontrib><creatorcontrib>Torri, V</creatorcontrib><creatorcontrib>Floriani, I</creatorcontrib><creatorcontrib>Jayson, G</creatorcontrib><creatorcontrib>Lamont, A</creatorcontrib><creatorcontrib>Tropé, C</creatorcontrib><creatorcontrib>The ICON and AGO Collaborators</creatorcontrib><creatorcontrib>ICON and AGO Collaborators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parmar, M K B</au><au>Ledermann, J A</au><au>Colombo, N</au><au>du Bois, A</au><au>Delaloye, J-F</au><au>Kristensen, G B</au><au>Wheeler, S</au><au>Swart, A M</au><au>Qian, W</au><au>Torri, V</au><au>Floriani, I</au><au>Jayson, G</au><au>Lamont, A</au><au>Tropé, C</au><aucorp>The ICON and AGO Collaborators</aucorp><aucorp>ICON and AGO Collaborators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2003-06-21</date><risdate>2003</risdate><volume>361</volume><issue>9375</issue><spage>2099</spage><epage>2106</epage><pages>2099-2106</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.
In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects.
With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0·82 [95% CI 0·69–0·97], p=0·02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% CI for difference 1–12]), and median survival of 5 months (29 vs 24 months [1–11). 717 patients developed progressive disease or died. The progression-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0·76 [0·66–0·89], p=0·0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4–15]) and in median progression-free survival of 3 months (13 vs 10 months [1–5]).
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12826431</pmid><doi>10.1016/S0140-6736(03)13718-X</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2003-06, Vol.361 (9375), p.2099-2106 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2069947668 |
| source | MEDLINE; Business Source Complete; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Baldness Cancer Cancer therapies Carboplatin - administration & dosage Chemotherapy Cisplatin - administration & dosage Clinical trials Disease-Free Survival Drug Administration Schedule Drug dosages Fatalities Female Humans Medical treatment Middle Aged Motivation Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Paclitaxel Paclitaxel - administration & dosage Patients Platinum Quality of Life Survival Toxicity Womens health |
| title | Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T07%3A48%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paclitaxel%20plus%20platinum-based%20chemotherapy%20versus%20conventional%20platinum-based%20chemotherapy%20in%20women%20with%20relapsed%20ovarian%20cancer:%20the%20ICON4/AGO-OVAR-2.2%20trial&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Parmar,%20M%20K%20B&rft.aucorp=The%20ICON%20and%20AGO%20Collaborators&rft.date=2003-06-21&rft.volume=361&rft.issue=9375&rft.spage=2099&rft.epage=2106&rft.pages=2099-2106&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(03)13718-X&rft_dat=%3Cproquest_cross%3E2069947668%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199077001&rft_id=info:pmid/12826431&rft_els_id=S014067360313718X&rfr_iscdi=true |